Neoadjuvant Therapy
Low-dose aspirin reduces colorectal cancer recurrence for patients with PI3K mutations
Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K pathway, according to results of the randomized ALASCCA study presented at ASCO Gastrointestinal Cancers Symposium.
VIDEO: OlympiA trial shows olaparib’s benefits for patients with BRCA mutations ‘persist’
SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.
‘Be very suspicious’: Staging of early pancreatic cancer inaccurate up to 80% of the time
Nearly 80% of individuals clinically diagnosed with stage I pancreatic ductal adenocarcinoma and close to 30% diagnosed with stage II disease got upstaged after surgery, according to retrospective study results.
City of Hope Orange County appoints executive medical director of colorectal surgery
Alessio Pigazzi, MD, PhD, has been appointed executive medical director of colorectal surgery at City of Hope Orange County.
Neoadjuvant immunotherapy may broaden surgery eligibility for hepatocellular carcinoma
Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.
Fox Chase Cancer Center appoints division chief of surgical oncology
Sanjay S. Reddy, MD, FACS, has been appointed division chief of surgical oncology at Fox Chase Cancer Center.
Adding mRNA vaccine to immunotherapy cuts risk for melanoma recurrence nearly in half
CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.
A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer
CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.
Keytruda extends survival in high-risk triple negative breast cancer
A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.
Aspirin may have ‘direct role’ in augmenting the immune system to fight colorectal cancer
Whereas previous studies have shown aspirin use decreases incidence and mortality of colorectal cancer, researchers may now have insight into why this occurs, according to study results published in Cancer.